Participated · Series C · Sep 2025

CUTISS develops denovoSkin™, a personalized bio‑engineered human skin graft that is currently in Phase 3 clinical trials in Europe. The company is advancing an automated manufacturing platform for personalized tissue therapy to enable scalable production of its grafts. CUTISS is preparing denovoSkin™ for commercialization and is also working toward the market launch of VitiCell®. The proceeds from its recent financing will support the Phase 3 program, industrialization of the automation platform, and commercialization preparations. The company has raised more than CHF 125M in total to date, reflecting prior financings alongside the latest round. CUTISS is headquartered in Zurich and is collaborating with clinical partners to expand production capacity in Europe. CUTISS develops human skin grafts and focuses on skin regenerative medicine and tissue engineering. The company provides personalized and automated skin-tissue treatments for patients with large-area and deep skin defects. Its core product offering is tailored skin grafts intended to address significant wound and defect cases. CUTISS's technology emphasizes automation and personalization in manufacturing therapeutic skin tissue. The company recently completed a new financing round, strengthening its balance sheet for further development and deployment of its therapeutic products. CUTISS develops denovoSkin™, an automatically produced personalized skin tissue therapy intended to treat large and deep skin defects including burns. denovoSkin™ is the company’s lead product candidate and completed a Phase I pediatric clinical trial at the University Children’s Hospital in Zurich. Phase II studies are currently ongoing in Switzerland and the European Union and are partially funded by Wyss Zurich. CUTISS plans to scale manufacturing at the Biotechnopark in Zurich‑Schlieren and to implement a prototype machine to automate production of large quantities of skin from a small healthy biopsy. The company aims to file for market authorization for denovoSkin™ in Switzerland and the EU in 2022. CUTISS was founded in 2017 as a spin-off of the University of Zurich after more than 15 years of research. The recent Series B financing will support clinical completion, manufacturing scale-up, and regulatory submissions.